FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288045952> ?p ?o ?g. }

• W4288045952 endingPage "213047" @default.
• W4288045952 startingPage "213047" @default.
• W4288045952 abstract "Lapatinib (L) and fulvestrant (F) are used in targeted anticancer therapies, in particular, against phenotypically different breast cancer cells. L, a dual inhibitor of EGFR and HER2 tyrosine kinases, is active against HER2-positive breast cancer cells, while F, a selective estrogen receptor degrader (SERD), is active against ER-positive breast cancer cells. However, the action of L and F can be limited due to their relatively low water solubility and bioavailability. In the present study, poly(amidoamine) (PAMAM) dendrimer G3 was functionalized with L or F or L and F to compare their effects with free L or F against breast cancer cells with different receptor status (ER-positive MCF-7, triple negative MDA-MB-231 and HER2-positive SK-BR-3 cells). L-PAMAM and F-PAMAM conjugates potentiated cytostatic and cytotoxic action of L and F that was accompanied by elevated levels of autophagy. TRDMT1, RNA methyltransferase, was also involved in this response as judged by TRDMT1 nuclear translocation and nano-drug resistance of TRDMT1 gene knockout cells. Nano-drugs also promoted elimination of doxorubicin-induced senescent breast cancer cells by apoptosis-mediated senolysis regardless of receptor status. In conclusion, we propose a novel anticancer approach based on L-PAMAM and F-PAMAM nanoplatforms being effective, at least, against breast cancer cells with different phenotypic features." @default.
• W4288045952 created "2022-07-27" @default.
• W4288045952 creator A5002514020 @default.
• W4288045952 creator A5003129718 @default.
• W4288045952 creator A5005663257 @default.
• W4288045952 creator A5018254700 @default.
• W4288045952 creator A5034200711 @default.
• W4288045952 creator A5055901305 @default.
• W4288045952 date "2022-09-01" @default.
• W4288045952 modified "2023-10-16" @default.
• W4288045952 title "Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status" @default.
• W4288045952 cites W1518308640 @default.
• W4288045952 cites W1966042314 @default.
• W4288045952 cites W1968343003 @default.
• W4288045952 cites W1973021352 @default.
• W4288045952 cites W1981853312 @default.
• W4288045952 cites W1983964788 @default.
• W4288045952 cites W1989676936 @default.
• W4288045952 cites W1994930469 @default.
• W4288045952 cites W2005311687 @default.
• W4288045952 cites W2008260047 @default.
• W4288045952 cites W2013086386 @default.
• W4288045952 cites W2022504862 @default.
• W4288045952 cites W2041441484 @default.
• W4288045952 cites W2043561943 @default.
• W4288045952 cites W2045563337 @default.
• W4288045952 cites W2046056065 @default.
• W4288045952 cites W2048595517 @default.
• W4288045952 cites W2067114310 @default.
• W4288045952 cites W2069519394 @default.
• W4288045952 cites W2073439757 @default.
• W4288045952 cites W2104222297 @default.
• W4288045952 cites W2114273672 @default.
• W4288045952 cites W2123388712 @default.
• W4288045952 cites W2123583989 @default.
• W4288045952 cites W2128807350 @default.
• W4288045952 cites W2146670754 @default.
• W4288045952 cites W2149076882 @default.
• W4288045952 cites W2149984051 @default.
• W4288045952 cites W2157811842 @default.
• W4288045952 cites W2169708904 @default.
• W4288045952 cites W2187976253 @default.
• W4288045952 cites W2275209600 @default.
• W4288045952 cites W2431617775 @default.
• W4288045952 cites W2479426178 @default.
• W4288045952 cites W2534336764 @default.
• W4288045952 cites W2559942094 @default.
• W4288045952 cites W2593198694 @default.
• W4288045952 cites W2602350547 @default.
• W4288045952 cites W2749722012 @default.
• W4288045952 cites W2750174947 @default.
• W4288045952 cites W2765905079 @default.
• W4288045952 cites W2785091318 @default.
• W4288045952 cites W2791899207 @default.
• W4288045952 cites W2805168616 @default.
• W4288045952 cites W2890167612 @default.
• W4288045952 cites W2933268643 @default.
• W4288045952 cites W2949258280 @default.
• W4288045952 cites W2970817168 @default.
• W4288045952 cites W2979579292 @default.
• W4288045952 cites W3026473791 @default.
• W4288045952 cites W3029435888 @default.
• W4288045952 cites W3033832055 @default.
• W4288045952 cites W3042236956 @default.
• W4288045952 cites W3044596243 @default.
• W4288045952 cites W3109746568 @default.
• W4288045952 cites W3111207111 @default.
• W4288045952 cites W3131322387 @default.
• W4288045952 cites W3146830857 @default.
• W4288045952 cites W3166058209 @default.
• W4288045952 cites W3168632835 @default.
• W4288045952 cites W3184754552 @default.
• W4288045952 cites W3205240380 @default.
• W4288045952 cites W4210317772 @default.
• W4288045952 cites W4221091893 @default.
• W4288045952 cites W4223596746 @default.
• W4288045952 doi "https://doi.org/10.1016/j.bioadv.2022.213047" @default.
• W4288045952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35917687" @default.
• W4288045952 hasPublicationYear "2022" @default.
• W4288045952 type Work @default.
• W4288045952 citedByCount "7" @default.
• W4288045952 countsByYear W42880459522023 @default.
• W4288045952 crossrefType "journal-article" @default.
• W4288045952 hasAuthorship W4288045952A5002514020 @default.
• W4288045952 hasAuthorship W4288045952A5003129718 @default.
• W4288045952 hasAuthorship W4288045952A5005663257 @default.
• W4288045952 hasAuthorship W4288045952A5018254700 @default.
• W4288045952 hasAuthorship W4288045952A5034200711 @default.
• W4288045952 hasAuthorship W4288045952A5055901305 @default.
• W4288045952 hasBestOaLocation W42880459521 @default.
• W4288045952 hasConcept C121608353 @default.
• W4288045952 hasConcept C126322002 @default.
• W4288045952 hasConcept C185592680 @default.
• W4288045952 hasConcept C190283241 @default.
• W4288045952 hasConcept C2776694085 @default.
• W4288045952 hasConcept C2777329042 @default.
• W4288045952 hasConcept C2779786085 @default.
• W4288045952 hasConcept C2780482068 @default.

• next